Biotech grants in Norway
Explore Biotech grants for companies in Norway. This list brings together funding for drug discovery, diagnostics, cell and gene therapy, biomanufacturing and life-science research from Norwegian innovation agencies, research funders and foundations, international programs open to applicants in Norway, and competitions any company can enter, with the deadline, award size and eligibility on every listing. Grants aimed at Biotech in Norway come first.
Showing 193-216 of 623 grants
Svalbard Business Development Grant
🇳🇴Innovation Norway · Norway
Funds companies carrying out business development projects on Svalbard through a grant and advisory support.
Verification: Research Commercialisation from Publicly Funded Research Organisations
🇳🇴RCN · Norway
Funds Norwegian research organisations, their tech transfer offices, and spin-out startups maturing new technology toward commercial use through the Research Council of Norway's Verification: Research Commercialisation scheme.
KAPPA — 1st for Proposals
🇨🇿TA CR · Czechia
Funds Czech and partner institutions through EEA-style cross-border applied-research collaborations.
Student Entrepreneurship Grant (STUD-ENT)
🇳🇴Innovation Norway · Norway
Funds student teams at Norwegian universities and colleges developing and commercialising a business idea through a grant.
GREGoRi Innovation Projects
NIH · United States
Funds a genuinely new experimental or computational approach to finding the cause of a rare genetic disorder, where the current state of the art falls short.
FY26 Reconstructive Transplant Research Program Concept Award
CDMRP · United States
Funds small, high-risk exploratory research into reconstructive transplantation and vascularized composite allotransplantation for wounded Service Members and Veterans.
Xcelerate Champion of Innovation
WHX Tech · United Arab Emirates
Pays an equity-free cash prize to the top healthcare startup pitching live at WHX Tech's Xcelerate competition in Dubai.
Developing novel theory and methods for understanding the genetic architecture of complex human traits (R01)
NIH · United States
Funds theory and method development on how genetic and non-genetic factors together produce variation in complex traits, tested against large existing datasets.
Strategic Research Agreement — Round 1
Breakthrough T1D · United States
Funds investigator-led type 1 diabetes research partnerships across preclinical discovery, treatment, and translational priorities.
Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01)
NIH · United States
Funds new analysis of clinical, genomic, environmental and registry data that already exists, to sharpen who is at risk of cancer and what happens to them.
Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research
NIH · United States
Funds the development and hard technical validation that turns a working cancer research technology into one other laboratories will actually adopt.
Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research
NIH · United States
Funds proof-of-concept work on a genuinely new tool, assay, platform or instrument for characterising cancer cells or handling biospecimens.
Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21)
NIH · United States
Funds the same reanalysis of already-collected cancer data on a smaller, exploratory footing, for teams that do not need a full research project award.
Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant
NIH · United States
Funds exploratory studies of the ethical, legal and social consequences of human genetics, especially where a technology or a use of genomic data is new.
Ethical, Legal and Social Implications (ELSI) Research
NIH · United States
Funds a full research project on the ethics, law and social effects of human genetics — and refuses to review an application with no diverse-perspectives plan.
Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD)
NIH · United States
Funds one bundled run from first-in-human through phase 2a for a dementia drug that works on something other than amyloid or tau.
Lupus Insight Prize
LRA · United States
Provides prize recognizing a specific significant recent lupus research discovery through the Lupus Insight Prize.
Developing novel theory and methods for understanding the genetic architecture of complex human traits (R21)
NIH · United States
Funds the exploratory version of the same theory-and-methods work on complex trait variation, for ideas that need testing before a larger project is justified.
Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01)
NIH · United States
Funds work on how GLP-1 and related drugs change cancer risk — raising it for some cancers, lowering it for others.
Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21)
NIH · United States
Funds smaller, higher-risk work on how GLP-1 and related drugs change cancer risk. No clinical trial in this version.
National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis
NIH · United States
Funds a Phase 0, I or II cancer trial that the investigator designed, inside one of six named National Cancer Institute programme areas.
NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders
NIH · United States
Funds Phase I trials for heart, lung, blood and sleep disorders — and pays for the final preclinical work needed to start one.
Minor Use Minor Species Development of Drugs
FDA · United States
Funds the safety and effectiveness testing costs of getting a designated new animal drug through FDA approval.
BRAIN Initiative: Development and Validation of Novel Tools to Probe Cell-Specific and Circuit-Specific Processes in the Brain
NIH · United States
Funds new genetic or non-genetic tools that deliver genes, proteins or chemicals to specific brain cells or circuits, with validation built in.